What the analyst said

Piper Sandler analyst Billy Fitzsimmons assumed coverage on Oracle (NYSE: ORCL) with an Overweight rating and a price target of $240.00.

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Where the price stands

ORCL trades at $115. The 22 analysts who set a target in the last 3 months range from $155 to $400, with a median of $233. This $240 target is 3% above the median.

Since the note ORCL has moved −30% (from $165). 12-month window: day 276 of 365, closes on February 2, 2027.

Track record

This call✓ Target reached on June 1, 2026, 4 months after the note.

Firm track recordPiper Sandler: 78% of its 37 targets at least a year old were reached within 12 months (#15 of 26 firms). Accuracy ranking →

Piper Sandler on Oracle

Piper Sandler price targets on Oracle

4 calls from February 2, 2026 to July 6, 2026. The target went from $240 to $225 (−6%). The rating stayed Buy.

Piper Sandler targetORCL share price
  1. July 6, 2026Kept the $225 targetBuy$225
  2. June 11, 2026Target raised from $210 (+7%)Buy$225
  3. March 11, 2026Target cut from $240 (−13%)Buy$210
  4. February 2, 2026 This noteEarliest call shownBuy$240
Share
Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.